- Farampator
-
- $34.00 / 5mg
-
2026-05-11
- CAS:211735-76-1
- Min. Order:
- Purity: 99.84%
- Supply Ability: 10g
|
| | FARAMPATOR Basic information |
| Product Name: | FARAMPATOR | | Synonyms: | FARAMPATOR;CX 691;Org 24448;CX-691; ORG2444;Org2444;CX 691; ORG 24448; CX-691; CX691;Methanone, 2,1,3-benzoxadiazol-5-yl-1-piperidinyl-;Org24448, CX-691 | | CAS: | 211735-76-1 | | MF: | C12H13N3O2 | | MW: | 231.25 | | EINECS: | | | Product Categories: | | | Mol File: | 211735-76-1.mol |  |
| | FARAMPATOR Chemical Properties |
| Boiling point | 398.3±34.0 °C(Predicted) | | density | 1.299±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMF: 30 mg/ml; DMF:PBS (pH7.2) (1:40): 25μg/ml; DMSO: 20 mg/ml | | form | A crystalline solid | | pka | -1.33±0.36(Predicted) | | color | White to off-white |
| | FARAMPATOR Usage And Synthesis |
| Uses | Farampator has shown effects as an AMPA receptor potentiator and glycine reuptake inhibitor with potential anti-psychotic efficacy and enhancement of prefrontal glutamatergic transmission. Farampator’s effects on both AMPA-PAMs and GlyT-1 inhibitor maybe also improve cognitive impairments in schizophrenia and in particular when combied with Risperidone (R525000). | | in vivo | Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.)[1]. Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Furthermore, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs[2]. |
| | FARAMPATOR Preparation Products And Raw materials |
|